• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Pharmacy World & Science

    Pharmacy World & Science

    Journal

    年发文量

    研究主题

    论文(2946)

    排序
    1A Note of Thanks
    Derar H. Abdel-Qader, Zamzam Mohamed Ismail Ahmed,Gazala Akram, Angela Alexander, Anna Almarsdottir,Filipa Alves da Costa,Claire Anderson, S. M. Arend,Parisa Aslani, Z. Babar, Douglas Ball, Peri J. Ballantyne,
    2010
    引用
    AI阅读
    加入学术空间
    2Gastric Ulcer in a Child Treated with Deferasirox
    Tiene Bauters,Veerle Mondelaers,Hugo Robays,Kathleen Hunninck,Barbara de Moerloose

    We present a patient with thalassemia major who developed a gastric ulcer, probably related to the use of deferasirox. Although gastric ulcer is mentioned as infrequent adverse event in the scientific product information of deferasirox, in our current knowledge, this is the first case-report on this adverse drug reaction. The severity of this event justifies the reporting of this case.

    2010引用:16
    引用
    AI阅读
    加入学术空间
    3Detection of Drug Related Problems in an Interdisciplinary Health Care Model for Rural Areas in Germany
    Thomas Fiss,Christoph Alexander Ritter,Dietrich Alte,Neeltje van den Berg,Wolfgang Hoffmann

    Objective The disparity between an increasing complexity of patients' treatment and the declining number of general practitioners (GP) require action. The AGnES-concept (general practitioner-relieving, community-based, e-health assisted, systemic intervention) is based on the delegation of original physician-activities to qualified AGnES-practice assistants. Purposes of AGnES part 1 were to determine the feasibility of community-based home medication reviews (HMR) and the establishment of a health professional network to identify drug related problems (DRP) in the domicile of elderly patients. Two consecutive studies (AGNES 2 + 3) were conducted to implement HMR. Setting General practices on the isle of Rugia in Mecklenburg-Western Pomerania, a German rural area. Patients who receive regular home visits by their GP were addressed. Method Study-instruments for the feasibility study (AGnES 1) were designed by an expert panel and modified for the implementation (AGnES 2 + 3) studies. HMR were conducted by additionally qualified AGnES-practice assistants regarding DRP like drug-drug interaction (DDI), adverse drug reactions (ADR), and compliance. DRP-selection was inspired by the coding system Pi-Doc. Pharmacists checked DRP and intervened, if necessary. 18 (AGnES 1) and 60 (AGnES 2 + 3) geriatric patients received a minimum of two home visits by an AGnES-practice assistant. Main outcome measure Feasibility was assessed by patients' satisfaction with care provided by the AGnES-practice assistant. For implementation reported DRP and the conducted interventions were evaluated. Results During AGnES 1 a documentation sheet was developed and tested. 56 potential DDI were identified. 37 of 112 drugs which caused potential interactions were attributed to OTC medication and food components. 84% of respondents judged the systematic evaluation of their pharmacotherapy as helpful. During AGnES 2 + 3 local pharmacists identified DDIs in 45% of patients. Seven patients (11.6%) reported at least one ADR attributable to their current medication. Those patients who received a second HMR (n = 29) during AGnES 2 + 3 rated the HMR as reasonable 65.5% (n = 19), and partly reasonable 24.1% (n = 7). Conclusions By comprehensive HMR conducted by AGnES-practice assistants in delegation of the patients' GPs in cooperation with local pharmacists we could identify a considerable prevalence of DRP under real-life conditions. Further studies should recruit more participants including a control group with usual care.

    2010引用:32
    引用
    AI阅读
    加入学术空间
    4Appropriateness of Timing of Drug Administration in Electronic Prescriptions
    Arwa Hassan,Walter E. Haefeli

    INTRODUCTION:For a small number of drugs circadian variability has been shown to modify efficacy, safety, or pharmacokinetics.OBJECTIVE OF THE STUDY:We aimed to develop a database containing optimum timing of drug administration and to test how well such information is considered in daily practice.SETTING:University hospital providing primary and tertiary care.METHODS:We included data of randomised controlled trials collected from Embase and Medline studying the impact of the timing of drug administration on pharmacodynamics, pharmacokinetics, and adverse events. Data were analysed and weighed according to an algorithm considering trial design and assessed endpoints. Each branch of the algorithm led to a specific recommendation as to the time of the day the drug should be administered. A second algorithm was used to establish a recommendation if studies differed in their conclusion. Subsequently we retrospectively analysed the dosing time in consecutive electronic prescriptions issued at our institution in 2007.RESULTS:For 30 active compounds randomised controlled trials were published assessing optimum timing of their administration. In 33% of them timing had no impact on clinical endpoints while the administration at a certain time of the day significantly improved the outcome of another 64% no clear statement was made for one drug (ketoprofen). We then analysed 478,864 electronic prescriptions. Two percent of them contained drugs with known circadian variability. Only in 14% the suggested time was considered with a range between 0% for telmisartan (bedtime administration) and 85% for perindopril (morning administration).CONCLUSION:Thus far, dedicated studies on circadian responsiveness to drugs are sparse and for the few drugs with unequivocal evidence this information is only rarely considered in daily practice. Integration of circadian dosing information into a clinical decision support system linked to electronic prescribing may be one promising way to make this information widely accessible.

    2010引用:11
    引用
    AI阅读
    加入学术空间
    5Introduction of Pharmaceutical Expertise in a Palliative Care Team in Sweden
    Barbro Norrström, Ing-Britt Cannerfelt,Helen Frid, Kim Roos, Helena Ramström

    OBJECTIVE:This paper presents for the first time the inclusion of dispensing pharmacists, a special group of pharmacy professionals, in a Swedish palliative care team. It also presents the drug stock management in the medication room of the clinical area and the improvement of drug logistics. In addition to a dispensing pharmacist, a pharmacist was included in this part of the project as well.SETTING:The palliative care team at ASIH Långbro Park, Sweden.METHOD:The intervention with the dispensing pharmacists as new members of the interdisciplinary palliative team was evaluated by a questionnaire to the staff. An inventory of the different drugs in stock was performed in March 2006 and in April 2007, respectively. The inventory turnover rate was determined and the drug consumption for the last 6 months of 2005 and 2006, respectively, was also analysed.MAIN OUTCOME MEASURES:The questionnaire used rating scales allowing participants to rate the questions/statements. The number of different drugs and drug packages in stock were recorded during the inventories. Drug costs were calculated and the inventory turnover rate was determined by dividing the annual cost of drugs by the value of the inventory. Drug consumption was analysed using the Xplain statistical programme, a statistical tool from Apoteket AB.RESULTS:The overall impression of the dispensing pharmacists was positive. The staff reported advantages in having a dispensing pharmacist present at ASIH not only for the drug logistics, but also for drug-related queries. The inventory of the drug stock and the drug-handling process resulted in a 14% reduction of product numbers and a 36% reduction in the tied-up capital for drugs in stock. The inventory turnover rate increased from 6.7 to 9.5. A 7% reduction of medication costs was also observed when comparing the last 6 months of 2006 with the costs in 2005.CONCLUSION:The principal result of this project is that inclusion of pharmaceutical expertise on a palliative care team can be a valuable asset for the team in pharmaceutical issues and of great benefit for stock management, including cost savings and improvement of drug logistics.

    2010引用:13
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2946 篇论文

    高被引作者

    作者引用发文
    Nicholas Barber103711
    H. J. M. Beijer8061
    C.J. de Blaey8061
    G. Iain Carpenter8021
    Marianne Schroll8021
    Graziano Onder8021
    Daniela Fialova8021
    Liv Wergeland Sorbye8021
    Eva Topinkova8021
    Roberto Bernabei8021

    高产作者

    作者引用发文
    J W Foppe Van Mil60638
    Ludo Willems12628
    Benoit Allenet33924
    Gert Laekeman43523
    Steven Simoens43922
    Hekster Yechiel A25222
    Fernando Fernandez-Llimos34922
    Fikret Vehbi Izzettin5818
    l beretz017
    Bouvy Marcel L35117

    相关期刊

    Pharmacy world & science : PWS
    International Journal of Clinical Pharmacy
    Pharmaceutisch Weekblad
    International Journal of Pharmacy Practice